R-Biopharm AG today announced that it has entered into a collaboration with Bosch Healthcare Solutions. Under the agreement, R‑Biopharm AG develops, manufactures and commercializes molecular diagnostic tests for Bosch Healthcare Solutions’ Vivalytic, a fully automatic all-in-one platform.
Darmstadt and Waiblingen, Germany, March 1st, 2018 – The Vivalytic platform supports a broad spectrum of technologies including several methods of molecular PCR- and microarray-testings. It is applicable for the processing of diverse biological material covering fluids, tissue and sputum samples. The system combines nucleic acid purification with the requested assay and is expected to provide qualitative and quantitative detection results in short analysis time. R‑Biopharm AG will offer a new product line specially developed for the Vivalytic platform, providing multiplex and economical low- and singleplex infection panels. The Vivalytic portfolio will comprise assays that cover various indications, such as respiratory diseases and sexually transmitted infections (STI). Additional application areas will be companion diagnostics, antibiotic drug-resistance and human- and pharmacogenetic testing.
“We are pleased to partner with Bosch Healthcare Solutions”, said Dr. Ralf Dreher, CEO at R-Biopharm AG. “The combination of Bosch Healthcare Solutions’ technology competencies and R-Biopharm’s knowledge in development of clinical diagnostics brings the innovation of integrated systems for nucleic acid analysis to a higher level.” Frank Apostel, Vice President Business Development and Companion Diagnostics at R‑Biopharm AG said “The introduction of Vivalytic and our new product line will enable healthcare professionals to make earlier and more accurate decisions to improve patient’s care.” Marc Meier, General Manager of Bosch Healthcare Solutions GmbH said “With R-Biopharm we have inspired an important partner for the platform, with whom we can jointly expand the Vivalytic test portfolio for clients. The core competencies of Bosch in automation, miniaturization and networking are complemented by R-Biopharm’s expertise in developing and commercializing innovative diagnostic solutions.”
R‑Biopharm expects to begin initial sales of Vivalytic products in the third quarter of 2018. Financial terms of the agreement were not disclosed.
About R-Biopharm:
R-Biopharm AG (Darmstadt, Germany) is a globally active life science company and a leading provider of reliable test systems for clinical diagnostics, companion diagnostics and for analyzing human food and animal feedstuffs.
Since 1988, R-Biopharm has been developing innovative products characterized by top quality, reliability and efficiency. A strong sense of responsibility, long-standing experience and a network of more than 20 affiliated companies and subsidiaries in Europe, the US, Brazil, Latin America, China, India and Australia, as well as more than 120 distribution partners, make R-Biopharm a prime partner for clients from retail, industry and public institutions looking for answers and solutions for current and analytical challenges.
About Bosch Healthcare Solutions:
Bosch Healthcare Solutions GmbH is a wholly-owned subsidiary of Robert Bosch GmbH. The subsidiary was established in 2015 with the aim of developing products and services that improve people’s health and quality of life. About 100 associates (2017) are currently employed at the company’s headquarters in Waiblingen, Germany. The subsidiary’s solutions draw on the Bosch Group’s core competencies: sensors to collect data, software to evaluate that data, and services based on this data analysis.
